States have identified six susceptibility loci in or near biologically plausible candidate genes. However, these loci have not been replicated in an independent European sample. We performed a genetic replication study of previously identified TGCT susceptibility loci in a Croatian case-control sample and performed additional analyses as concerning histological subtypes or tumor staging. We analyzed six single-nucleotide polymorphisms [rs2900333 (ATF7IP), rs210138 (BAK1), rs755383 (DMRT1), rs995030 (KITLG), rs4624820 (SPRY4), and rs4635969 (TERT/ CLPTM1L)], each representing one of the published susceptibility loci/genes. Five susceptibility loci were found to be also associated in the Croatian population with P-values between 2.1e-10 (rs995030; odds ratio [OR] 3.08) and 0.01739 (rs4635969; OR 1.37), which remained statistically significant after correction for multiple testing. Although rs2900333 near ATF7IP just showed borderline association with all-TGCT (OR 1.24, P = 0.062), it showed significant association with the more aggressive forms of the tumor (OR 1.51, P = 0.0067)-a clinically interesting finding, which however has to be replicated in an independent sample. Assessment of cumulative risks revealed that men with at least seven risk alleles have a more than 2.5-fold increased disease risk (OR = 2.73, 95% confidence interval = 1.98-3.79). In summary, we independently replicated the majority of TGCT susceptibility loci identified previously in a Croatian sample and suggested a possible role of genetic variation near ATF7IP in regulating disease progression.
Introduction
In young men, aged 15-45, testicular germ-cell tumor (TGCT) is the most frequent malignant disease. Histologically, TGCTs can be divided in two major subclasses, seminomas and nonseminomas, and both are believed to arise from common progenitor germ cells (1) . In line with this assumption, there is currently no evidence of specific clustering of the different histological subtypes within families with multiple cases of TGCT (2) . Known risk factors for TGCT include the occurrence of a previous germ-cell tumor, a positive family history, infertility, cryptorchidism and testicular microlithiasis (3) (4) (5) . According to the 2009 TNM Classification of Malignant Tumors, the following staging is used for TGCT: Stage I is localized to the testis with no evidence for metastases, Stage II shows metastases in retroperitoneal and/or para-aortic lymph nodes, whereas Stage III is characterized by metastasis beyond the retroperitoneal and para-aortic lymph nodes (6) . In addition to environmental risk factors contributing to disease etiology, several epidemiologic studies have revealed that TGCTs have a pronounced degree of heritability (3, 7) . Indeed, the heritability of TGCT was estimated to be up to 0.25, the third highest among all cancers (8) . To unravel underlying common genetic risk factors for TGCT, genome-wide association studies have been conducted in case-control samples from Great Britain and the United States, which until now identified six loci significantly associated with TGCT (9) (10) (11) (12) . However, if compared with other complex inherited diseases, there is a relative lack of independent replication studies in TGCT so far and indeed just a few patient samples of sufficient size have been reported, which on the other hand would be a prerequisite for future genetic meta-analyses to further elucidate the genetic basis of TGCT susceptibility.
Although some of the isolated island populations in Croatia are characterized by high rates of inbreeding (13) , as a whole the modern Croatian population is heterogeneous and represents a typical mixture of genetic pools in a European population (14) . A recent epidemiological study on TGCT in Croatia showed a rapid increase in incidence with an estimated annual percent change of 7% in a period of 25 years (3.1 mean age standardized rate between 1983 and 1987 compared with 11.2 mean age standardized rate between 2003 and 2007), being one of the highest increase rates worldwide (15) . The goal of this study was to perform the first independent replication study of identified TGCT susceptibility loci in an European population. Six loci/genes were considered: ATF7IP, BAK1, DMRT1, KITLG, SPRY4 and TERT/CLPTM1L, and six single-nucleotide polymorphisms (SNPs), each representing one of the published susceptibility loci, were genotyped in a group of 325 Croatian patients with TGCT. Allele frequencies of patients were compared with a male, tumor-free control sample of the same ethnic population. We further evaluated the possible effect of these loci on histological subclasses, clinical staging and their cumulative disease risk for TGCT.
Materials and methods

Description of patients and controls
A total of 325 Croatian patients with a primary testis tumor (Table 1) were ascertained by the Departments of Oncology and Urology at the Clinical Hospital Centre Zagreb, Croatia. All patients gave their written informed consent and completed a detailed questionnaire together with the attending physician including information about their geographical origin, risk factors, familiar history of TGCT, clinical status, age at diagnosis and localization of disease. Based on histological reports, patients were classified as having seminoma or nonseminoma (the latter including choriocarcinomas, teratomas, yolk sac, embryonal and mixed carcinomas). Patients were classified as having a less aggressive form of disease if the cancer was categorized as Stage I according to the 2009 TNM Classification of Malignant Tumors (6) . In all other cases, the patients were classified as having a more aggressive form. Bilateral cases were not included in either group (see also Table 1 ). The control group consisted of 331 Croatian males aged 50 or older, who had no kind of malignant tumor and in whose family no case of TGCT was known. They were selected from blood donors at the Croatian Institute for Transfusion Medicine, Zagreb, Croatia. Written informed consent was obtained from each individual after detailed explanation of the purpose of the study. The study was approved by the ethics committees of the Clinical Hospital Centre Zagreb, Croatia, Croatian Institute for Transfusion Medicine, Zagreb, Croatia, and the University of Ulm, Germany.
Genetic analysis
Extraction of genomic DNA from whole-blood samples was performed by a standard salting-out method. The SNPs rs2900333, rs210138, rs755383, rs995030, rs4624820 and rs4635969 were selected for genotyping because of their significant association with TGCT in published genome-wide association analyses, with each of the six published susceptibility loci being represented by one SNP. Genotyping of SNPs was carried out on a TaqManTM platform with assays designed by Applied Biosystems, Foster city, CA (assay ID C__15849470_10, ID C____940463_20, ID C___1690720_10, ID C___8716323_20, ID C__27983854_10 and ID C___1844186_10).
Statistical analysis
Categorical variables were described with absolute and relative frequency distributions; quantitative variables were summarized using means, medians, standard deviations and quartiles. For each SNP, a possible deviation from Hardy-Weinberg equilibrium was assessed in the control sample using an exact test as described in the software package PLINK (16) . The CochranArmitage test for trend was used for testing association between genotype and phenotype. The six P-values from the trend tests based on all cases and controls were adjusted for multiple testing by the Bonferroni-Holm step-down procedure. The corrected values are additionally reported in Table 2 , whereas in the text, raw P-values are quoted. Unconditional logistic regression analysis was applied to determine profile likelihood odds ratios (OR) per risk allele. These analyses were performed using the software package PLINK (16) . In order to assess the cumulative genetic risk with regard to the six loci, the total number of risk alleles was determined for each participant. A number of seven risk alleles were used to separate the group with 'low number' of risk alleles (less than seven) and 'high number' (at least seven), and logistic regression was applied to calculate the corresponding OR after defining the participants with less than seven risk alleles as the reference group. Logistic regression with the number of risk alleles as the independent variable was also applied to calculate the area under the receiver operating characteristic curve (AUC) as a measure of discrimination between cases and controls. It is the area under the curve in a graph of (1 -specificity) against sensitivity obtained when varying the threshold between the 'low number' and the 'high number' group. The latter analyses were carried out using SAS, version 9.2.
Results
We have genotyped six SNPs in altogether 325 Croatian TGCT cases and 331 controls, overall allele call rates on the TaqManTM platform were >98.8%. All six SNPs passed the statistical test for Hardy-Weinberg equilibrium (minimal P-value in controls: P = 0.11 for rs2900333). Five variants were nominally associated with TGCT also in the Croatian population, whereas one (rs2900333) showed borderline association with an uncorrected P-value of 0.0624 ( Table 2 ). The five positive associations remained significant after conservative correction for multiple testing by the Bonferroni-Holm step-down procedure. As expected from previous studies, the lowest P-value and the greatest effect size were observed for SNP rs995030 at the KITLG locus, which is actually the highest ever reported for any cancer analyzed to date (17) . TGCT risk in the Croatian sample was increased almost 3-fold per copy of the major G allele of rs995030 (OR = 3.08, 95% confidence interval [CI] = 2.15-4.41, unadjusted P = 2.1e-10). The four other SNPs with weaker association (rs755383, rs210138, rs4624820 and rs4635969) were associated with TGCT at lower levels of statistical significance (uncorrected P-values between 0.000235 and 0.0174), however, both the effect size and the direction of effects in our study were similar to those previously published ( Table 2 ). Unlike two previous reports (11, 18) , we found no statistically significant difference in genotype frequencies between the two major histological subclasses of TGCT, seminomas and nonseminomas (Supplementary Table 1 , available at Carcinogenesis Online) for any of the six SNPs analyzed, which again is compatible with the assumption that both histological subtypes arise from common progenitor cells and share a common biological basis.
Genetic association studies in TGCT have so far failed to report a consistent statistically significant difference in genotype frequencies between various risk factors or histological subclasses. Further, the previous studies did not observe differences between sporadic, familial and bilateral cases. We have, therefore, chosen to analyze a possible association with different tumor staging categories as a marker of differences in tumor aggressiveness. Of all cases, 160 individuals were assigned to Stage I, whereas 163 patients were categorized as being Stage II or III. The five SNPs, which already showed nominal significance in the primary analysis, showed no obvious difference in this secondary analysis. Although we could observe a trend for some of them, levels of association for the less aggressive and more aggressive forms of disease did not differ significantly for any of these SNPs. Interestingly, however, rs2900333 near ATF7IP, which just showed borderline association with all-TGCT (OR = 1.24, 95% CI = 0.99-1.56, P = 0.062), showed a pronounced association with the more aggressive forms of the tumor (OR = 1.51, 95% CI = 1.12-2.03, P = 0.0067; Table 3 ) compared with the cases categorized as Stage I (OR = 1.03, 95% CI = 0.78-1.36, P = 0.823). Notably, testing for association when patients categorized as Stage I are regarded as the control group and patients categorized as Stage II and III are regarded as the cases also yielded a significant per-allele OR of 1.47 (95% CI = 1.04-2.08, P = 0.028), and this deviation remains after adjusting for tumor subtype (OR = 1.72, P = 0.0048).
To further delineate this finding, we performed a third line of analysis. We assessed the ATF7IP-stage findings stratified according to Significant P-values are depicted in bold. Per-allele OR from previous studies are adopted from (28).
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tumor subtypes. Among stage II/III tumors, the tumor subtype had no major influence on the strength of association between genotype and disease although there might be a trend toward a larger effect in nonseminomas (seminoma: n = 39 patients, OR = 1.55, P = 0.102; nonseminoma: n = 108 patients, OR = 1.55, P = 0.012). However, in Stage I tumors, seminomas show only a moderately lower OR than Stage II/III patients (n = 86 patients, OR = 1.38, P = 0.082), whereas nonseminomas do not seem to exhibit an association with ATF7IP (n = 70 patients, OR = 0.75, P = 0.113). This leads to an overall OR = 1.43 for seminomas and OR = 1.13 for nonseminomas, which could not be proven to be statistically different from each other in our rather small cohort. We could, therefore, provide first evidence that genetic variation near ATF7IP may be associated with progression of the disease, which might be of future clinical significance. We further investigated the cumulative effects of all six loci (SNPs rs210138, rs2900333, rs755383, rs995030, rs4624820 and rs4635969) if comparing subgroups with less than seven or seven and more risk alleles. Indeed, seven risk alleles is the median number of risk alleles in cases, and the majority of cases had seven or more risk alleles (65%). The median number of risk alleles in controls on the contrary was six and only 40% of controls had seven or more risk alleles, which is the third quartile of the distribution in controls (Figure 1 ). In individuals with seven or more risk alleles, the risk was increased more than two and a half-fold (OR = 2.73, 95% CI = 1.98-3.79) if compared with individuals who carry less than seven risk alleles. The AUC obtained when varying the threshold between the two risk groups is 66.8% (95% CI = 62.7-70.9%) in comparison with 50% with a random classification of cases and controls. We observed no difference concerning age at onset, histology, clinical stage or laterality of the disease between cases with more risk alleles (10 and 11) compared with those with less risk alleles (3 and 4).
Discussion
During the past years, four genome-wide association studies for TGCT have identified several risk variants in samples from the UK and the USA, which are reported to be in or near six biologically plausible candidate genes. The KITLG-KIT pathway is supposed to regulate survival, proliferation and migration of primordial germ cells (19) . Somatic activating mutations of KIT were found in sporadic, bilateral and familial TGCT cases (20, 21) . Furthermore, KITLG was also reported to be significantly associated with TGCT in mice (22) . This locus shows the strongest association with TGCT with a risk increase per risk allele of more than 2.3-fold; moreover, it until now shows the highest effect of any susceptibility variant previously observed in all different types of cancers (17) . In addition, a recent genome-wide association study of testicular dysgenesis syndrome among Scandinavian men also found a significant association of TGCT with the KITLG locus (23) . Two further genes, BAK1 (BCL2-antagonist/killer 1), which induces apoptosis, and SPRY4 (Sprouty homolog 4), which suppresses the mitogen-activated protein kinase signaling pathway, are also involved in KIT signaling (24) . DMRT1 (Doublesex-and mab-3-related transcription factor 1) is involved in sex determination and differentiation and is also reported to be associated with TGCT in mice (25). TERT (telomerase reverse transcriptase) and ATF7IP (activating transcription factor 7-interacting protein 2) are involved in the maintenance of telomere length (26) . In addition, a replication study of BAK1, DMRT1, KITLG, SPRY4 and TERT/CLPTM1L showed that the risk variants also predispose to familial and bilateral cases (27) . In our analysis, we carried out the first independent replication study of all six susceptibility loci in a European population. According to recent epidemiological data (15), we have included around 15% of all TGCT patients in Croatia in the last 20 years. Of the six SNPs tested, five were associated with TGCT also in the Croatian population and even the remaining SNP showed borderline association with a similar effect size as published in other populations. Association studies of TGCT have so far not found a consistent difference in the association for different histological subtypes, which is also confirmed in our study. Our results provide further evidence that both seminoma and nonseminoma originate from the same primordial germ cell and that the differentiation evolves later during tumor development. Most notably, this is the first study to investigate the association of susceptibility loci for TGCT with the aggressiveness of disease. Of all six SNPs, only rs2900333 near ATF7IP, which was in a nominal sense not significantly associated with all TGCT, showed significant association with the more aggressive forms. Interestingly, an excess of risk alleles could not be detected in low-stage patients with nonseminomas, a fact that also hints to a role of ATP7IP in the development of aggressive tumors. ATF7IP is frequently overexpressed in human cancer and is implicated in the regulation of telomere length (28) . Furthermore, it was shown that mice with shorter telomeres have increased incidence of metastases (29) . In addition, it was shown previously that ATP7IP regulates the expression of TERT (29) ; it is therefore intriguing that we observed a trend in the TERT/CLPTM1L locus suggesting that it might be associated with less-aggressive disease progression. These data suggest a distinct role of telomere maintenance in the regulation of clinical progression of TGCT. Distinguishing the role of telomere maintenance, however, requires further work and should be the focus of future studies. To investigate whether our data might be biased by the inclusion of a larger proportion of prevalent cases, we first analyzed the distribution of staging categories in cases diagnosed before 2009 and those diagnosed in 2009-11. This analysis showed a similar distribution of aggressive versus nonaggressive cases in both time periods (diagnosis before 2009: 49% nonaggressive versus 51% aggressive cases; diagnosis 2009-11: 52% nonaggressive versus 48% aggressive cases). Moreover, the relative proportion of different histological TGCT subtypes is similar in our cohort compared with all TGCT cases in Croatia diagnosed in the last 20 years (T. Kulis unpublished results; data source: Croatian National Cancer Registry). We have, therefore, no indication that there may be a bias by the inclusion of a large number of prevalent cases. Although ATF7IP represents a plausible candidate gene for the promotion of metastases, it is worth noting that the genetic power of our study was limited due to the relatively low number of cases. Further, as this independent second line of analysis was performed to generate new working hypotheses, we did not correct P-values for multiple testing. It is therefore evident that this finding needs to be evaluated and possibly confirmed in independent samples before it might be used as a tool for clinical risk assessment.
In addition, we assessed the cumulative TGCT risk for risk alleles at all six loci. We found that carriers of seven or more risk alleles had a 2.73-fold increased risk of developing TGCT compared with men carrying less then seven risk alleles. In order to assess at which probability a randomly chosen patient with TGCT had a higher risk than a randomly chosen control, we estimated the area under a corresponding receiver operating characteristic curve. The resulting AUC value of 66.8% was rather similar to a previous study (30) , which estimated the AUC value from the published genome-wide association studies GWAS, being 69.2%. Similar to other studies (30, 31) , we thus find that the cumulative risk effect is currently not feasible for clinical utility, which however may change in the future if additional susceptibility variants are identified by associated meta-analyses or additional studies with rare variants.
In conclusion, our findings confirm that the previously identified loci are involved in the susceptibility for TGCT. Our results also provide the first indication that rs2900333 might influence the aggressiveness of TGCT in the Croatian population and suggest a possible role of ATF7IP in regulating the clinical progression of TGCT, although the later finding has to be replicated in independent samples. 
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